FDA on COX-2
The committees will discuss the overall benefit to risk considerations (including cardiovascular and gastrointestinal safety concerns) for COX-2 selective nonsteroidal anti-inflammatory drugs and related agents.
Visit Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. It's running Feb. 16-18, 2005. They invite public participation.
Electronic comments should be submitted to http://www.fda.gov/dockets/ecomments. Select "2004N-0559-Overall Benefit to Risk Considerations for COX-2 Selective Nonsteroidal Anti-inflammatory Drugs and Related Agents" and follow the prompts to submit your statement.
I tried to find this docket in their system; I wasn't able to. Maybe you will have better luck.
Comments on this post
Post a Comment
Links to this post
Create a Link